Skip to main content
SpringerLink
Log in

Antibiotika und Chemotherapeutika

  • Chapter
Arzneiverordnungs-Report 2003

  • 97 Accesses

Zusammenfassung

Im Gesamtgebiet der Antiinfektiva bilden die Antibiotika neben den antibakteriellen Chemotherapeutika aus dem Bereich der Sulfonamide, Chinolone (Gyrasehemmer) und Nitroimidazole sowie den Virostatika weiterhin die praktisch bedeutsamste Gruppe. Bei den einzelnen Infektionskrankheiten ist die Indikation für eine antibiotische Therapie sehr unterschiedlich zu stellen. Während bei symptomatischen Harnwegsinfektionen die Gabe von Antibiotika oder Chemotherapeutika fast immer obligat ist, werden akute Atemwegsinfektionen, vor allem die akute Bronchitis, in mehr als 90% der Fälle durch Viren ausgelöst und sind daher keine primäre Indikation für Antibiotika.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Absher J.R., Bale J.R Jr. (1991): Aggravation of myasthenia gravis by erythromycin. J.Pediatr. 119:155–156.

    Article  PubMed  CAS  Google Scholar 

  • Archer G.L., Polk R.E. (2001): Approach to therapy for bacterial diseases. Braunwald E. et al. (eds.): Harrison’s principles of internal medicine. McGraw-Hill Medical Publishing Division, New York, pp. 867–882.

    Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2003): Rote-Hand-Brief: Telithromycin (Ketek®). Pharm. Ztg. 148: 1421.

    Google Scholar 

  • Balfour J.A. B., Wiseman L.R. (1999): Moxifloxacin. Drugs 57: 363–373.

    Article  PubMed  CAS  Google Scholar 

  • Baquero F. (1999): Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J. Antimicrob. Chemother. 11(Suppl. 1): 35–43.

    CAS  Google Scholar 

  • Brockmeyer N. (1998). Rationale für die antiretrovirale Therapie. Dtsch. Ärztebl. 95: C-313–316.

    Google Scholar 

  • Cadisch R., Streit E., Hartmann K. (1996): Exazerbation einer Myasthenia gravis pseudoparalytica nach Azithromycin (Zithromax®). Schweiz. Med. Wochenschr. 126:308–310.

    PubMed  CAS  Google Scholar 

  • Cummings K.J., Lee S.M., West E.S., Cid-Ruzafa J., Fein S.G., Aoki Y., Sulkowski M.S., Goodman S.N. (2001): Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 285:193–199.

    Article  PubMed  CAS  Google Scholar 

  • Daschner F. (2002): Antibiotika am Krankenbett. 12. Aufl., Springer-Verlag, Berlin, Heidelberg, New York.

    Google Scholar 

  • Dybul M., Fauci A.S., Bartlett J.G., Kaplan J.E., Pau A.K. and the Panel on Clinical Practices for Treatment of HIV (2002): Guidelines for using antiretzroviral agents among HIV-infected adults and adolescents. Ann. Intern. Med. 137(5 Pt. 2): 381–433.

    PubMed  Google Scholar 

  • Egger M., May M., Chêne G., Phillips A.N., Ledergerber B., Dabis F. et al. and the ART Cohort Collaboration (2002): Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119–129.

    Article  PubMed  Google Scholar 

  • Elies W., Grünewald T., Kern W.V. (2003): Infektionen der oberen Luftwege. In: Deutsche Gesellschaft für Innere Medizin (Hrsg.): Rationelle Diagnostik und Therapie in der Inneren Medizin. Urban & Fischer, München, Ergänzungslieferung 14, Kapitel L3.

    Google Scholar 

  • Granizo J.J., Aguilar L., Casal J., dal Re R., Baquero R (2000): Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J. Antimicrob. Chemother. 46: 959–964.

    Article  PubMed  CAS  Google Scholar 

  • Haidvogl M., Schuster R., Heger M. (1996): Akute Bronchitis im Kindesalter. Multizenterstudie zur Wirksamkeit und Verträglichkeit des Phytotherapeutikums Umckaloabo. Z. Phytother. 17: 300–313.

    Google Scholar 

  • Howard J.R Ji. (1990): Adverse drug effects on neuromuscular transmission. Semin. Neurol. 10:89–102.

    Article  PubMed  Google Scholar 

  • Hurst M., Faulds D. (2000): Lopinavir. Drugs 60: 1371–1379.

    Article  PubMed  CAS  Google Scholar 

  • Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F (2002): Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents Chemother. 46: 2540–2545.

    Article  PubMed  CAS  Google Scholar 

  • Kayser O., Kolodziej H. (1997): Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med. 63: 508–510.

    Article  PubMed  CAS  Google Scholar 

  • Matthys H., Eisebitt R., Seith B., Heger M. (2003): Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 10(Suppl.4): 7–17.

    Article  PubMed  Google Scholar 

  • May E.F., Calyert P.C. (1990): Aggravation of myasthenia gravis by erythromycin. Ann. Neurol. 28: 577–579.

    Article  PubMed  CAS  Google Scholar 

  • Mocroft A., Vella S., Benfield T.L., Chiesi A., Miller V. et al. (1998): Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725–1730.

    Article  PubMed  CAS  Google Scholar 

  • N.N. (2003): Telithromycin: new preparation. A needless addition to the other macrolides. Prescrire Int. 12: 8–11.

    Google Scholar 

  • Naber K.G., Adam D. (1998): Einteilung der Fluorchinolone. Chemotherapie Journal 7: 66–68.

    CAS  Google Scholar 

  • Pauker S.G., Kopelman R.I. (1993): Weak reasoning: diagnosis by drug reaction. N. Engl. J. Med. 328: 336–339.

    Article  PubMed  CAS  Google Scholar 

  • Pijpers E., van Rijswijk R.E., Takx-Kohlen B., Schrey G. (1996): A clarithromycininduced myasthenie syndrome. Clin. Infect. Dis. 22: 175–176.

    Article  PubMed  CAS  Google Scholar 

  • Reinert R.R., Al-Lahham A., Lemperle M., Tenholte C, Briefs C, Haupts S. et al. (2002a): Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J. Antimicrob. Chemother. 49:61–68.

    Article  PubMed  CAS  Google Scholar 

  • Reinert R.R., Al-Lahham A., Lütticken R., Boos M., Schmitz F.-J. (2002b): Characterization of clinical streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. J. Antimicrob. Chemother. 49: 1015–1018.

    Article  PubMed  CAS  Google Scholar 

  • Wutzler P., De Clercq E., Wutke K., Färber I. (1995): Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J. Med. Virol. 46: 252–257.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Winfried V. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universitat Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwabe, U., Kern, W.V. (2004). Antibiotika und Chemotherapeutika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18512-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40188-9

  • Online ISBN: 978-3-642-18512-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation